Alerts will be sent to your verified email
Verify Email
AUROPHARMA
|
Aurobindo Pharma
|
Alkem Laboratories
|
Abbott India
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
865.0 . | 185.0 . | n/a |
|
Number of ANDA's Approved By USFDA
|
733.0 . | 160.0 . | n/a |
|
US DMF Filings
|
310.0 . | n/a | n/a |
|
Europe DMF Filings
|
2109.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
4.7 % | 3.5 % | 0.02 % |
|
Financials
|
|||
|
5 yr Average ROE
|
12.72 % | 17.38 % | 30.11 % |
|
5yr average Equity Multiplier
|
1.46 | 1.39 | 1.43 |
|
5yr Average Asset Turnover Ratio
|
0.68 | 0.86 | 1.14 |
|
5yr Avg Net Profit Margin
|
12.5 % | 14.54 % | 18.53 % |
|
Price to Book
|
2.03 | 5.49 | 14.56 |
|
P/E
|
19.5 | 28.82 | 42.44 |
|
5yr Avg Cash Conversion Cycle
|
-46.37 Days | -61.46 Days | -46.68 Days |
|
Inventory Days
|
59.62 Days | 56.11 Days | 45.22 Days |
|
Days Receivable
|
30.33 Days | 44.62 Days | 19.34 Days |
|
Days Payable
|
121.28 Days | 122.42 Days | 109.21 Days |
|
5yr Average Interest Coverage Ratio
|
43.54 | 24.48 | 97.37 |
|
5yr Avg ROCE
|
15.27 % | 22.76 % | 38.77 % |
|
5yr Avg Operating Profit Margin
|
19.22 % | 18.44 % | 23.42 % |
|
5 yr average Debt to Equity
|
0.19 | 0.18 | 0.0 |
|
5yr CAGR Net Profit
|
-8.16 % | 6.44 % | 15.41 % |
|
5yr Average Return on Assets
|
8.64 % | 12.47 % | 21.03 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
51.82 % | 51.2 % | 74.99 % |
|
Share Pledged by Promoters
|
17.5 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-0.01 % | -5.96 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
10.34 % | 7.52 % | 2.11 % |
|
Aurobindo Pharma
|
Alkem Laboratories
|
Abbott India
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|